Valeo Financial Advisors LLC bought a new stake in Eli Lilly and Co (NYSE:LLY) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,485 shares of the company’s stock, valued at approximately $3,463,000. Eli Lilly and accounts for about 0.8% of Valeo Financial Advisors LLC’s portfolio, making the stock its 22nd largest position.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Edgestream Partners L.P. acquired a new stake in Eli Lilly and during the 1st quarter worth about $1,708,000. Colonial Trust Advisors grew its position in Eli Lilly and by 107.8% during the 1st quarter. Colonial Trust Advisors now owns 32,903 shares of the company’s stock worth $2,639,000 after purchasing an additional 17,066 shares during the period. Kovitz Investment Group Partners LLC grew its position in Eli Lilly and by 2.1% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 7,450 shares of the company’s stock worth $627,000 after purchasing an additional 151 shares during the period. OLD Mutual Customised Solutions Proprietary Ltd. grew its position in Eli Lilly and by 18.2% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 15,482 shares of the company’s stock worth $1,302,000 after purchasing an additional 2,382 shares during the period. Finally, First Financial Equity Corporation acquired a new stake in Eli Lilly and during the 1st quarter worth about $252,000. 76.31% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently commented on LLY. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen reaffirmed a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 4th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research note on Friday, October 13th. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $92.14.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 251,088 shares of company stock valued at $22,041,236. Insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $86.10 on Thursday. Eli Lilly and Co has a 12-month low of $74.00 and a 12-month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market cap of $94,800.00, a P/E ratio of 41.00, a PEG ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter last year, the firm earned $0.88 EPS. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. analysts forecast that Eli Lilly and Co will post 4.22 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.61%. Eli Lilly and’s payout ratio is 99.05%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.